The maraviroc expanded access program - Safety and efficacy data from an open-label study

HIV Clinical Trials

Volumn 16, Issue 1, 2015, Pages 10-21

  Lazzarin, Adriano ^a   Reynes, Jacques ^b   Molina, Jean Michel ^c   Valluri, Srinivas ^d   Mukwaya, Geoffrey ^d   Heera, Jayvant ^d   Craig, Charles ^e,f   Van Der Ryst, Elna ^e,f   Sierra Madero, Juan G ^g  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b GUI DE CHAULIAC HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PFIZER INC   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^f INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^g Research Network   (United Kingdom)

Author keywords

Antiretroviral agents; Darunavir; Etravirine; HIV; Maraviroc; Raltegravir

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; MARAVIROC; RALTEGRAVIR; TRIACYLGLYCEROL LIPASE; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; DARUNAVIR; PYRIDAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIVIRAL THERAPY; ANUS CANCER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BLURRED VISION; BOWEN DISEASE; CARCINOMA IN SITU; CD4 LYMPHOCYTE COUNT; COMPASSIONATE USE; CONGESTIVE HEART FAILURE; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEART ARREST; HEART VENTRICLE TACHYCARDIA; HEMOGLOBIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERTENSIVE CRISIS; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; IMMUNE EVASION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PENIS CARCINOMA; PEPTIC ULCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; SIDE EFFECT; SKIN ALLERGY; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THORAX PAIN; THROMBOCYTE COUNT; TONGUE CANCER; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VERTIGO; VIRAL TROPISM; VIRUS IMMUNITY; VIRUS RESISTANCE; ADOLESCENT; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; HEALTH CARE DELIVERY; MIDDLE AGED; PROGRAM EVALUATION; VERY ELDERLY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; CCR5 RECEPTOR ANTAGONISTS; CD4 LYMPHOCYTE COUNT; CYCLOHEXANES; DARUNAVIR; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROGRAM EVALUATION; PYRIDAZINES; RALTEGRAVIR POTASSIUM; TREATMENT OUTCOME; TRIAZOLES; VIRAL LOAD; YOUNG ADULT;

EID: 84939611466     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1179/1528433614Z.0000000002     Document Type: Article

References (23)

1. Selzentry [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2014.
2. Celsentri [summary of product characteristics]. http://www.medicines.org.uk/emc/medicine/20386. Accessed May 19, 2014.
3. Gulick RM, Lalezari J, Goodrich J, et al. MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429-1441.
4. Fätkenheuer G, Nelson M, Lazzarin A, et al. MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359:1442-1455.
5. Hardy WD, Gulick RM, Mayer H, et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr. 2010;55:558-564.
6. + T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Antivir Ther. 2011;16:395-404.
7. Clotet B, Bellos N, Molina JM, et al. POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-1178.
8. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355-365.
9. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. JVirol.2007;81:2359-2371.
10. Roche M, Salimi H, Duncan R, et al. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology. 2013;10:43.
11. Feyertag F, Xiang X, Lewis M, et al. Population dynamics of R5-tropic HIV-1 associated with maraviroc resistance. Antivir Ther. 2013;18:A34.
12. Swenson LC, Chui CK, Brumme CJ, et al. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure. Antimicrob Agents Chemother. 2013;57:6122-6130.
13. th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA, USA.
14. th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA.
15. Thompson MA, Aberg JA, Cahn P, et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333.
16. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. 11-3-2013; Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents; Convened by the Department of Health and Human Services (DHHS): 1-139.
17. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis. 2007;196:304-312.
18. Garred P, Madsen HO, Petersen J, et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol. 1998;25:1462-1465.
19. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203:35-40.
20. Dean M, Jacobson LP, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res. 1999;59:3561-3564.
21. Moreno C, Gustot T, Nicaise C, et al. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology. 2005;42:854-862.
22. Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother. 2008;52:858-865.
23. Lazzarin A, Than S, Valluri SR, Heera J, Mukwaya G. Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program. HIV Clin Trials. 2012;13:83-89.